AIDS and Behavior

, 10:249

Monitoring Adherence to HIV Antiretroviral Therapy in Routine Clinical Practice: The Past, the Present, and the Future

Original Paper

Keywords

HIV adherence resistance electronic medication monitor CASI mediset pill box organizer 

REFERENCES

  1. Artinian, N.T., Harden, J.K., Kronenberg, M.W., Vander Wal, J.S., Daher, E., & Stephens, Q. (2003). Pilot study of a Web-based compliance monitoring device for patients with congestive heart failure. Heart Lung, 32(4), 226–233.PubMedCrossRefGoogle Scholar
  2. Bangsberg, D.R., Acosta, E., Gupta, R., Guzman, D., Riley, E.D., & Harrigan, P.R. (2005). Differences in protease and non-nucleoside reverse transcriptase inhibitor adherence-resistance relationships are explained by virologic fitness. AIDS, 20(2), 223–231.CrossRefGoogle Scholar
  3. Bangsberg, D.R., Bronstone, A., Chesney, M.A., & Hecht, F.M. (2002). Computer-assisted self-interviewing (CASI) to improve provider assessment of adherence in routine clinical practice. Journal Acquired Immune Deficiency Syndrome, 31(Suppl. 3), S107–S111.Google Scholar
  4. Bangsberg, D.R., Charlebois, E.D., Grant, R.M., Holodniy, M., Deeks, S.G., & Perry, S. (2003). High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS, 17(13), 1925–1932.PubMedCrossRefGoogle Scholar
  5. Bangsberg, D.R., Hecht, F., Clague, H., Charlebois, E., Ciccarone, D., & Chesney, M. (2001). Provider assessment of adherence to HIV antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 26(5), 435–442.PubMedGoogle Scholar
  6. Bangsberg, D.R., Hecht, F.M., Charlebois, E.D., Zolop, A.R., Holodniy, M., & Sheiner, L. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14(4), 357–366.PubMedCrossRefGoogle Scholar
  7. Bangsberg, D.R., Perry, S., Charlebois, E.D., Clark, R.A., Roberston, M., & Zolopa, A.R. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS, 15(9), 1181–1183.PubMedCrossRefGoogle Scholar
  8. Bova, C.A., Fennie, K.P., Knafl, G.J., Dieckhaus, K.D., Watrous, E., & Williams, A.B. (2005). Use of electronic monitoring devices to measure antiretroviral adherence: Practical considerations. AIDS Behavior, 9(1), 103–110.CrossRefGoogle Scholar
  9. de Olalla, G., Knobel, H., Carmona, A., Guelar, A., Lopez-Colomes, J.L., & Cayla, J.A. (2002). Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal Acquired Immune Deficiency Syndrome, 30(1), 105–110.CrossRefGoogle Scholar
  10. Gross, R., Bilker, W.B., Friedman, H.M., Coyne, J.C., & Strom, B.L. (2002). Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS, 16(13), 1835–1837.PubMedCrossRefGoogle Scholar
  11. Gross, R., Zhang, Y., & Grossberg, R. (2005). Medication refill logistics and refill adherence in HIV. Pharmacoepidemiology and Drug Safety.Google Scholar
  12. Hogg, R., Heath, K., Bangsberg, D.R., Yip, B., Press, N., & O’Shaughnessy, M.V. (2002). Intermittent use of Triple Combination Therapy is Predictive of Mortality at Baseline and after one year of follow-up AIDS. AIDS, 16, 1051–1058.PubMedCrossRefGoogle Scholar
  13. Jauhar, S. (2006). The demise of the physical exam. New England Journal of Medicine, 354(6), 548–551.PubMedCrossRefGoogle Scholar
  14. King, M.S., Brun, S.C., & Kempf, D.J. (2005). Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. Journal of Infectious Diseases, 191(12), 2046–2052.PubMedCrossRefGoogle Scholar
  15. Maggiolo, F., Ravasio, L., Ripamonti, D., Gregis, G., Quinzan, G., & Arici, C. (2005). Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clinical Infectious Diseases, 40(1), 158–163.PubMedCrossRefGoogle Scholar
  16. Mannheimer, S., Friedland, G., Matts, J., Child, C., & Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases, 34(8), 1115–1121.PubMedCrossRefGoogle Scholar
  17. Parienti, J., Massari, V., Descamps, D., Vabret, A., Bouvet, E., & Larouzé, B. (2004). Predictors of Virologic Failure and Resistance in HIV-Infected Patients Treated with Nevirapine or Efavirenz-Based Antiretroviral Therapy. CID, 38, 1311–1316.CrossRefGoogle Scholar
  18. Paterson, D.L., Swindells, S., Mohr, J., Brester, M., Vergis, E.N., & Squier, C. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medcine, 133(1), 21–30.Google Scholar
  19. Ruskin, P., Van der Wende, J., Clark, C., Fenton, J., Deveau, J., & Thapar, R. (2003). Feasibility of using the Med-eMonitor System in the treatment of Schizophrenia: A pilot study. Drug Information Journal, 37(3), 283–291.Google Scholar
  20. Simoni, J., Kurth, A., Pearson, C., Pantalone, D., Merrill, J., & Frick, P. (2006). Self-reported measures of antiretroviral therapy adherence. Aids and Behavior.Google Scholar
  21. Spacek, L.A., Shihab, H.M., Kamya, M.R., Mwesigire, D., Ronald, A., Mayanja, H., et al. (2006). Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clinical Infectious Diseases, 42(2), 252–259.PubMedCrossRefGoogle Scholar
  22. Weiser, S.D., Guzman, D., Riley, E.D., Clark, R., & Bangsberg, D.R. (2004). Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clinical Trials, 5(5), 278–287.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.University of CaliforniaSan FranciscoUSA

Personalised recommendations